Review



eplex bcid ruo panels  (BioFire Defense)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    BioFire Defense eplex bcid ruo panels
    Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of <t>ePlex</t> <t>BCID</t> panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID <t>RUO</t> or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).
    Eplex Bcid Ruo Panels, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/eplex bcid ruo panels/product/BioFire Defense
    Average 90 stars, based on 1 article reviews
    eplex bcid ruo panels - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)"

    Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

    Journal: Antimicrobial Agents and Chemotherapy

    doi: 10.1128/AAC.00441-21

    Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).
    Figure Legend Snippet: Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

    Techniques Used: Comparison

    Comparison of RDT platforms
    Figure Legend Snippet: Comparison of RDT platforms

    Techniques Used: Comparison, Bacteria



    Similar Products

    dx eplex ruo blood culture identification (bcid) gram-negative panel  (GenMark Diagnostics)
    90
    GenMark Diagnostics dx eplex ruo blood culture identification (bcid) gram-negative panel
    Dx Eplex Ruo Blood Culture Identification (Bcid) Gram Negative Panel, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dx eplex ruo blood culture identification (bcid) gram-negative panel/product/GenMark Diagnostics
    Average 90 stars, based on 1 article reviews
    dx eplex ruo blood culture identification (bcid) gram-negative panel - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    eplex bcid ruo panels  (BioFire Defense)
    90
    BioFire Defense eplex bcid ruo panels
    Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of <t>ePlex</t> <t>BCID</t> panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID <t>RUO</t> or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).
    Eplex Bcid Ruo Panels, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/eplex bcid ruo panels/product/BioFire Defense
    Average 90 stars, based on 1 article reviews
    eplex bcid ruo panels - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

    doi: 10.1128/AAC.00441-21

    Figure Lengend Snippet: Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

    Article Snippet: Recently, the ePlex BCID RUO panels were compared to the BioFire FilmArray blood culture ID (BCID) panel in 137 clinical blood cultures ( ).

    Techniques: Comparison

    Comparison of RDT platforms

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

    doi: 10.1128/AAC.00441-21

    Figure Lengend Snippet: Comparison of RDT platforms

    Article Snippet: Recently, the ePlex BCID RUO panels were compared to the BioFire FilmArray blood culture ID (BCID) panel in 137 clinical blood cultures ( ).

    Techniques: Comparison, Bacteria